Summary The cytotoxic and cytostatic responses of peripheral blood lymphocytes from eight cancer patients and splenocytes from four patients activated with rIL2 and a combination of rIL2 and rTNF-alpha were tested against two tumour cell lines. The cytotoxic response of rIL2-activated lymphocytes did not exceed the natural killer cytotoxicity values in all patients tested. In fact the killing capacity of some PBL deteriorated after rIL2 activation. The combined use of rIL2 and rTNF-alpha reversed this detrimental effect and enhanced the cytotoxic capacity of all PBL tested. In instances where high levels of killing were already achieved by rIL2 alone additional rTNF-alpha did not induce a significant change. This indicates that the role of rTNF-alpha may be to promote the response to rIL2 of PBL which react suboptimally to this lymphokine. rTNF-alpha did not only enhance cytotoxic capacity but also conferred cytostatic capacity to rIL2-activated LAK cells which were cytotoxic but unable to inhibit the growth of the surviving target cells. Natural killer cell selected K562 target cells which were less susceptible to killing by untreated lymphocytes than the parent K562 tumour cell line were killed more aggressively by rIL2 + rTNF-alpha LAK cells than by rIL2-LAK cells. No phenotypic differences were detected in these two cultures of LAK cells which indicates that the increased cytotoxic and cytostatic capacity of rIL2 +rTNF-alpha-LAK cells may be due to a higher state of activation of these cells or due to their capacity to recognise a broader spectrum of targets than rIL2-LAK cells.
The use of recombinant interleukin-2 (rIL2) in the activation of non-specific killer cells with the capacity to lyse naturalkiller (NK) resistant tumour cells has been extensively analysed (Grimm et al., 1982 (Grimm et al., , 1983 Muul et al., 1986) . Such cells, designated lymphokine-activated killer (LAK) cells, have been used for immunotherapy of cancer patients when combined with in vivo administration of IL2 (Rosenberg et al., 1985 (Rosenberg et al., , 1987 . The results of these human trials indicated that further work to increase the therapeutic effects and reduce the toxicity of this treatment is necessary. These goals may be achieved either by increasing the numbers or the cytotoxic potency of LAK cells administered combined with lower doses of rIL2. Recent experiments have demonstrated that activating peripheral blood lymphocytes (PBL) with anti-CD3 monoclonal antibody and rIL2 resulted in 1,000-fold expansion of LAK cell numbers. However, this required a culture period of 21 days and there was loss of LAK activity during the initial 12 days of culture (Ochoa et al., 1987) . These workers also demonstrated that the exogenous addition of beta-interleukin 1, interferon-beta or interferon-gamma can augment the lytic activity of cell populations expanded by anti-CD3 plus rIL2.
In this report we examined the capacity of recombinant tumour necrosis factor-alpha (rTNF-alpha) to enhance the lytic activity of rIL2-activated PBL in a 3-5 day in vitro culture system. The biological effects of TNF, previously known as cachectin (Beutler & Cerami, 1986) are diverse. Suppression of lipoprotein lipase activity enhancement of prostaglandin E2 and collagenase production by synovial cells and dermal fibroblasts, stimulation of bone resorption by osteoclasts and stimulation of procoagulant activity by vascular endothelial cells are amongst the spectrum of TNF induced events (Torti et al., 1985; Dayer et al., 1985; Bertolini et al., 1986; Nawroth & Stern, 1986) . The latter phenomenon which can cause vascular thrombosis and ischaemia of solid tumours has been associated with the antitumour actions of rTNF-alpha (Palladino et al., 1987) . rTNF-alpha is also directly cytotoxic for some human tumour cell lines and cytostatic or stimulatory for others but has no direct action on several tumour cells (Williamson et al., 1983; Sugarman et al., 1985; Ruggiero et al., 1987) .
The present study demonstrates that rTNF-alpha can also exert antitumour effects via its action on rIL2-activated LAK cells. rTNF-alpha added with rIL2 to a culture of PBL killing of MPCa targets ranged from -1.2 to 17.5% (Table I) . The response to IL2 of the PBL from the eight patients tested was not uniform. Cytotoxicity against K562 increased in three patients (nos 1, 4 and 7) by 60 to over 300% above the natural killer cytotoxicity values. The levels of killing remained almost unchanged in two patients (nos 5 and 8), while there was a considerable decrease in the cytotoxic capacity of PBL from the remaining three patients (nos 2, 3 and 6) after rIL2 activation. Cytotoxicity against MPCa increased 2-20-fold in six patients (nos 1, 4-8), remained stable in one (no. 2) and decreased in one (no. 3) ( Table I) .
The use of a combination of rIL2 and rTNF-alpha for activation resulted in the development of higher cytotoxic capacity by PBL from all patients tested compared to their non-activated or rIL2-activated counterparts. In one instance where a high level of killing was already achieved using rIL2 alone (patient no. 2), the level of specific killing did not change significantly by the addition of rTNF-alpha. The effect of rTNF-alpha was most pronounced on the PBL which did not develop high levels of killing due to rIL2 activation ( Table I ).
Development of cytostatic activity of PBL treated with rIL2 and a combination of rIL2 and rTNF-alpha On completion of the cytotoxicity assays the capacity of the effector cells to inhibit the growth of the surviving tumour target cells was examined. The results in Table II demonstrate that there was no correlation between the levels of cytotoxicity and cytostasis achieved by the untreated PBL. In spite of reasonable levels of natural killer activity in all test samples, cytostatic activity was present only in two against the K562 targets and in five against MPCa targets. Activation with rIL2 generated some cytostatic activity against K562 in all but two PBL samples. In these two samples (nos 3 and 7) the activated cells developed the capacity to stimulate the growth of K562 in spite of the fact that in patient no. 7 the cytotoxic activity of rIL2-activated LAK cells against this tumour was over 80%. rIL2 activation of PBL from patient no. 3 was detrimental to both cytotoxic and cytostatic responses.
The cytostatic activity against MPCa targets of all PBL samples increased 2-4-fold by rIL2 activation. Some samples (nos 4, 5 and 7), which had a pronounced stimulatory effect on these tumour cells, also became strongly inhibitory (Table  II) . The addition of rTNF-alpha to the activation cultures of the effector cells did not make a significant difference to the improved levels of cytostasis against MPCa achieved by PBL activated with rIL2 alone. Cytostasis against K562, however, was greatly improved when the lymphocytes were activated with rIL2 and rTNF-alpha. The detrimental effects of rIL2 activation on the cytostatic capacity of lymphocytes from patients 3 and 7 were reversed with the additional use of rTNF-alpha and the cytostatic capacity of lymphocytes from the remaining patients increased 2-6-fold (Table II) . Generation of cytotoxic activity in splenic lymphocytes using rIL2 and rTNF-alpha
The potential development of LAK activity from splenocytes was examined using cells from four spleens removed during surgical resection for gastro-oesophageal and pancreatic carcinoma. Untreated splenocytes from two patients had low cytotoxic activity against K562 and MPCa ranging from 18.5 to 27%, while splenocytes from the remaining two patients achieved levels of killing ranging from 45 to 67% (Table III) . Activation with rIL2 increased the cytotoxic capacity of the splenocytes from the former two patients to the range 30-45% and the latter to 72-95%. Preincubation of the splenocytes with additional rTNF-alpha did not confer further improvement to the latter group but significantly improved the cytotoxic potential of the former group with levels of killing within the range 33-81% (Table III) . 
Discussion
The results demonstrate that there is no correlation between the levels of NK cell killing of K562 and MPCa by the PBL of the different individuals examined. There are also differential changes in activity against these two targets in response to rIL2 activation (Table I ). This would suggest that different lytic mechanisms may be operating against these two targets, possibly via different effector cell populations. There is also no correlation between the cytotoxic capacity of the PBL and their potential to inhibit the proliferation of tumour target cells. This indicates that different mechanisms are involved in cytotoxicity and cytostasis, which is another multi-effector function mediated by several lymphocyte subsets (Matossian-Rogers & Taidi, 1983) . In the present experiments whole peripheral blood mononuclear cells containing monocytes were used and these can potentially contribute to cytotoxic and cytostatic reactions; we have, however, used these terms operationally to define a function rather than a particular cell type. Successful immunotherapeutic procedures must aim to enhance both these effector systems. Treatment of PBL with rIL2 did not improve the cytotoxic potential of all patients' lymphocytes. In fact the cytotoxic capacity of five out of eight samples remained either unaltered or deteriorated after 3 days' culture with rIL2 (Table I ). The generation of cytotoxic capacity in IL2-stimulated PBL is not only dependent on IL2 but also on the interaction of other lymphokines and cytokines produced by the stimulated cells. Large variations in the production of interferon-gamma, TNF-beta and TNF-alpha by IL2 stimulated PBL from different donors have been reported (Meager et al., 1987) .
Recent experiments demonstrate that the extent of activation of NK cells by exposure to IL2 is variable and donor-dependent (Titus et al., 1987) . This is possibly due to the different levels of synergising cytokines produced in response to IL2 by different donors. The results of Meager et al. (1987) demonstrate that production of TNF-beta by PBL was only weakly enhanced by rIL2 stimulation and in some donors TNF-alpha levels of rIL2-stimulated cultures (Philip & Epstein, 1986) , the induction of IL2 receptors on CD16+ large granular lymphocytes (0tensen et al., 1987) and ILI production by human monocytes and endothelial cells (Dinarello et al., 1986) .
In our experiments the incubation of patients' PBL with rIL2 and additional rTNF-alpha endowed the non-or lowresponders to rIL2 with high levels of cytotoxic capacity (Table I) . PBL which showed a strong response to rIL2 were not affected significantly by additional exposure to rTNFalpha. Culture of PBL with rTNF-alpha alone did not induce strong cytotoxic capacity in any of the samples tested (data not shown). Apart from the increased expression of receptors for IL2 induced by TNF-alpha the induction of peripheral blood mononuclear cells to secrete ILl may have a role in the enhanced killing capacity bf the patients' lymphocytes. Cytotoxic activity of large granular lympllocytes has been shown to be closely related to ILl production. Monocytes from patients with malignant disease have been shown to be defective in ILl production and have depressed NK cell activity (Son et al., 1982; Herman et al., 1984) . Herman et al. (1985) demonstrated that K562 target cells treated with ILI bound greater numbers of LGL than untreated target cells and defective cytotoxicity of LGL from patients with hepatocellular carcinoma could be corrected by treating the target K562 cells with ILI.
TNF-alpha used in combination with rIL2 not only improved the cytotoxic capacity of LAK cells but also their capacity to prevent the proliferation of the target cells (Table  II) . Cytotoxicity of tumour targets even at high effector to target cell ratios is rarely complete and surviving tumour cells can proliferate. Our results demonstrate that K562 target cells which survived NK cell cytotoxicity and grew out (K562 NKCS) are 60-73% more resistant to NK cells than the parent K562 population (Table IV) . Similar results were obtained with K562, which survived killing by LAK cells (data not shown). It is thus important that LAK cells exert a cytostatic effect on tumour cells as well as being cytolytic.
rTNF-alpha used in addition to rIL2 to generate LAK cell activity increased the cytostatic activity against K562 of all samples of PBL tested. Suzuki et al. (1987) demonstrated that tumour cells remained dormant in the peritoneal cavity of immune mice due to the cytostatic action of host cells induced by the synergistic action of IFN-gamma and TNF-alpha.
It appears that effector cells activated by the use of rIL2 and rTNF-alpha are more aggressive killers and also cytostatic. Phenotypic analysis of comparable cultures of LAK cells activated by rIL2 in combination with rTNFalpha showed no differences in these cell populations (data not shown). There were also no differences in cell numbers, indicating that there was no differential outgrowth of cell subsets (data not shown). The enhanced killing capacity of rIL2+rTNF-alpha-LAK cells may be due to a combination of factors, such as the induction of ILl production, the increased expression of IL2 receptors and other immunoregulatory effects of TNF-alpha on lymphocytes and monocytes, such as the induction of the synthesis of novel lytic or cytostatic proteins (Ruggiero et al., 1987) . Another possibility is the recognition of a broader spectrum of targets on tumour cells by rIL2+rTNF-alpha-LAK cells than by those activated by rIL2 alone. K562 target cells which survived killing by NK cells expressed a decreasing order of resistance to subsequent killing by NK, rIL2-LAK and rIL2+rTNF-alpha-LAK cells (Table IV) . One can postulate that rIL2-LAK cells recognise NK cell targets as well as another set of determinants while rIL2+rTNF-alpha-LAK cells recognise both these sets of targets and also a third family of target structures on tumour cells. Whatever the mechanism of the improved performance of rIL2+rTNF-alpha-LAK cells it is apparent that the additional use of rTNF-alpha in the preparation of LAK cells from PBL or splenocytes could improve the success rate of LAK cell immunotherapy.
